Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shares traded down 8.5% on Tuesday . The stock traded as low as $14.66 and last traded at $14.55. 28,413 shares traded hands during trading, a decline of 71% from the average session volume of 96,459 shares. The stock had previously closed at $15.90.
Rapport Therapeutics Stock Performance
The company's 50 day moving average price is $16.11 and its 200 day moving average price is $19.85.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its position in Rapport Therapeutics by 38.9% during the fourth quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock worth $86,000 after purchasing an additional 1,352 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Rapport Therapeutics in the third quarter worth $31,000. BNP Paribas Financial Markets bought a new stake in shares of Rapport Therapeutics during the 3rd quarter worth $34,000. The Manufacturers Life Insurance Company grew its stake in Rapport Therapeutics by 2.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company's stock valued at $1,584,000 after buying an additional 1,828 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Rapport Therapeutics in the 4th quarter worth $34,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
